Digital health company DarioHealth Corp (NASDAQ:DRIO) said on Thursday that it has secured a clinical study contract for its B2B diabetes platform.
The company has signed the agreement with an undisclosed pharmaceutical company that is seeking US FDA clearance for a new drug related to managing diabetes. DarioHealth will run and track the blood glucose readings of participants in the clinical study via its B2B diabetes platform.
DarioHealth's B2B platform aims to increase user engagement during the course of the clinical study and will leverage key learnings from its direct-to-consumer success, including allowing the participants to log their BGM readings in real-time in the Dario logbook and utilise the reminders and statistics features.
This move into clinical studies and clinician practices shows the adoption of Dario Blood Glucose Monitoring System products and solutions going beyond the scope of just the consumer.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial